| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2023 | Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine) | Bavli, Y; Chen, BM; Gross, G; Hershko, A; Turjeman, K; Roffler, S ; Barenholz, Y | Journal of Controlled Release 354, 316-322 | | | |
| 2019 | Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. | Bavli, Y; Winkler, I; Chen, BM; Roffler, S ; Cohen, R; Szebeni, J; Barenholz, Y | Journal of controlled release : official journal of the Controlled Release Society 306, 138-148 | | | |
| 2020 | PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. | Bavli, Y; Chen, BM; Roffler, SR ; Dobrovolskaia, MA; Elnekave, E; Ash, S; Barenholz, Y; Turjeman, K | Molecules (Basel, Switzerland) 25(3), 558 | | | |
| 2020 | Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex | Chen, E; Chen, BM; Su, YC; Chang, YC ; Cheng, TL; Barenholz, Y; Roffler, SR | ACS nano 14(7), 7808-7822 | | | |
